Posted 11 October, 2023
Walgreens Boots Alliance, Inc. appointed Timothy Charles Wentworth as new CEO
Nasdaq:WBA appointed new Chief Executive Officer Timothy Charles Wentworth in a 8-K filed on 11 October, 2023.
Appointment of Timothy Charles Wentworth as Chief Executive Officer and as a member of the Board of Directors
Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Walgreens Boots Alliance, Inc.
Retail/Wholesale • Drug Retail
Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.Market Cap
$17.8B
View Company Details
$17.8B
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Timothy Charles Wentworth as Chief Executive Officer and as a member of the Board of Directors On October 10, 2023, the Board of Directors (the "Board") of Walgreens Boots Alliance, Inc. (the "Company") appointed Timothy Charles Wentworth as Chief Executive Officer ("CEO") of the Company, effective as of October 23, 2023 (the "Effective Date"). Mr. Wentworth was also appointed as a member of the Board, effective as of the Effective Date. Mr. Wentworth, 63, previously served as Chief Executive Officer of Evernorth Health Services, a division of The Cigna Group ("Cigna"), from September 2020 to December 2021 and as President, Health Services of Cigna from February 2020 to December 2021. From December 2018, following the merger of Express Scripts Holding Company ("Express Scripts") with Cigna, until February 2020, Mr. Wentworth served as President, Express Scripts and Cigna Services. Prior to the aforementioned merger, he served as Chief Executive Officer of Express Scripts from May 2016 until December 2018 and in various leadership roles at Express Scripts from April 2012 until his appointment as Chief Executive Officer in May 2016. Mr. Wentworth serves as a member of the board of trustees of the University of Rochester, a director of the Concordance Academy of Leadership in St. Louis, Missouri and an executive committee member of the board of directors of the Opera Theatre of St. Louis. He previously served as a member of the board of trustees of Teachers College, Columbia University. In connection with his appointment as CEO, the Company entered into an employment agreement with Mr. Wentworth (the "Employment Agreement") setting forth the terms of his employment and compensation. The Employment Agreement has no specified term and his employment with the Company will be on an at-will basis. Pursuant to the Employment Agreement, Mr. Wentworth will be entitled to an initial annualized base salary of $1,500,000, subject to future adjustments as determined by the Company's Compensation and Leadership Performance Committee of the Board (the "Compensation Committee"), and will be eligible for an annual bonus with a target payout of 200% of base salary under the Company's corporate bonus program. Mr. Wentworth will also be eligible for long-term incentives pursuant to the WBA 2021 Omnibus Incentive Plan (the "Omnibus Plan") on the terms and conditions determined by the Compensation Committee. Subject to the approval of the Board or the Compensation Committee, within 60 days following the Effective Date, the Company will make an initial incentive equity grant to Mr. Wentworth with a grant date value equal to $12,000,000. This equity incentive award will be granted with terms and conditions consistent with the long-term incentive plan applicable to the Company's executive officers, which is expected to be comprised of 50% performance stock units and 50% restricted stock units, each vesting over three years. Mr. Wentworth will also be covered by the Company's Executive Severance and Change in Control Plan (as amended and restated effective August 6, 2019), a copy of which is filed as Exhibit 10.34 to the Company's Annual Report on Form 10-K for the fiscal year ended August 31, 2022 filed with the Securities and Exchange Commission on October 13, 2022 and which is incorporated herein by reference. Mr. Wentworth will also be entitled to relocation benefits and personal use of the Company's corporate aircraft up to a maximum of 75 hours per fiscal year. As a condition to his employment as CEO, Mr. Wentworth will enter into a non-competition, non-solicitation and confidentiality agreement with the Company. The foregoing description of Mr. Wentworth's Employment Agreement and compensation arrangements does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement which is attached as Exhibit 10.1 to this report and incorporated by reference herein. Mr. Wentworth has no family relationships with any director or executive officer of the Company, and there are no arrangements or understandings with any person pursuant to which he was selected as an officer of the Company. In addition, there have been no transactions directly or indirectly involving Mr. Wentworth that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). 2
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.